AIDS and Behavior

, Volume 15, Issue 7, pp 1465–1474 | Cite as

Determinants of Optimal Adherence Over Time to Antiretroviral Therapy Amongst HIV Positive Adults in South Africa: A Longitudinal Study

  • Dikokole Maqutu
  • Temesgen Zewotir
  • Delia North
  • Kogieleum Naidoo
  • Anneke Grobler
Original Paper

Abstract

Highly active antiretroviral therapy (HAART) requires strict adherence to achieve optimal clinical and survival benefits. A study was done to explore the factors affecting HAART adherence among HIV positive adults by reviewing routinely collected patient information in the Centre for the AIDS Programme of Research in South Africa’s (CAPRISA) AIDS Treatment Programme. Records of 688 patients enrolled between 2004 and 2006 were analysed. Patients were considered adherent if they had taken at least 95% of their prescribed drugs. Generalized estimating equations were used to analyse the data. The results showed that HAART adherence increased over time, however, the rate of increase differed by some of the socio-demographic and behavioural characteristics of the patients. For instance, HAART adherence increased in both urban and rural treatment sites over time, but the rate of increase was higher in the rural site. This helped identify sub-populations, such as the urban population, that required ongoing adherence counseling.

Keywords

Adherence HAART Generalized estimating equations (GEE) Longitudinal study Pill count approach 

References

  1. 1.
    Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMedGoogle Scholar
  5. 5.
    Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS. 2001;15(12):1591–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS. Patient-perceived barriers to antiretroviral adherence: associations with race. AIDS Care. 2002;14(5):607–17.PubMedCrossRefGoogle Scholar
  9. 9.
    Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care. 2004;16(4):471–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Penedo FJ, Gonzalez JS, Dahn JR, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res. 2003;54(3):271–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Roca B, Lapuebla C, Vidal-Tegedor B. HAART with didanosine once versus twice daily: adherence and efficacy. Int J Infect Dis. 2005;9(4):195–200.PubMedCrossRefGoogle Scholar
  12. 12.
    Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003;17(Suppl 3):S103–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Mohammed H, Kieltyka L, Richardson-Alston G, et al. Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDS. 2004;18(5):289–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMedGoogle Scholar
  16. 16.
    Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.PubMedCrossRefGoogle Scholar
  17. 17.
    Bangsberg D, Emenyonu N, Andia I, et al. No decline in high levels of electronic pill cap, unannounced home pill count, and patient-reported adherence to free ARV therapy over 12 months in rural Uganda. In: 15th conference on retroviruses and opportunistic infections. Boston, Massachusetts, 3–6 Feb 2008 [abstract no. 801]. http://www.retroconference.org/2008/index.asp. Accessed 4 Feb 2010.
  18. 18.
    Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16(1):38–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Muyingo SK, Walker AS, Reid A, et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2008;48(4):468–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17(9):1369–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Etard JF, Laniece I, Fall MB, et al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health. 2007;12(10):1191–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16(10):1363–70.PubMedCrossRefGoogle Scholar
  23. 23.
    Iliyasu Z, Kabir M, Abubakar IS, Babashani M, Zubair ZA. Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Niger J Med. 2005;14(3):290–4.PubMedGoogle Scholar
  24. 24.
    Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):281–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting early adherence to antiretroviral therapy amongst the HIV positive adults in South Africa. In: 50th annual conference of the South African statistical association, 29 Oct–2 Nov 2007. Johannesburg, South Africa.Google Scholar
  26. 26.
    South African National Department of Health. National antiretroviral treatment guidelines. 1st ed. (2004). http://www.hst.org.za/uploads/files/sa_ART_gudelines1.pdf/. Accessed 7 May 2009.
  27. 27.
    Littell RC, Milliken GA, Stroup WW, Wolfinger DR, Schabenberger O. SAS system for mixed models. 2nd ed. Cary, NC: SAS Institute Inc; 1999.Google Scholar
  28. 28.
    Milliken GA, Johnson E. Analysis of messy data. New York: Chapman & Hall/CRC; 2002.Google Scholar
  29. 29.
    Agresti A. Categorical data analysis. 2nd ed. New York: Wiley; 2002.CrossRefGoogle Scholar
  30. 30.
    Liang K-Y, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22.CrossRefGoogle Scholar
  31. 31.
    Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics. 2001;57:120–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Hedeker D, Gibbons R. Longitudinal data analysis. New York: Wiley; 2006.Google Scholar
  33. 33.
    Rubin DB. Inference and missing data. Biometrika. 1976;63:581–92.CrossRefGoogle Scholar
  34. 34.
    Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. New York: Wiley; 2002.Google Scholar
  35. 35.
    Fong OW, Ho CF, Fung LY, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med. 2003;4(2):133–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response California Collaborative Treatment Group. AIDS. 1999;13(9):1099–107.PubMedCrossRefGoogle Scholar
  37. 37.
    Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Skhosana N, Struthers H, Gray G, McIntyre J. HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa. AJAR. 2006;5(1):17–26.Google Scholar
  39. 39.
    Harvey KM, Carrington D, Duncan J, et al. Evaluation of adherence to highly active antiretroviral therapy in adults in Jamaica. West Indian Med J. 2008;57(3):293–7.PubMedGoogle Scholar
  40. 40.
    Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg. 2009;80(4):669–74.PubMedGoogle Scholar
  41. 41.
    Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9(7):51–4, 8.PubMedGoogle Scholar
  42. 42.
    Godin G, Cote J, Naccache H, Lambert LD, Trottier S. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care. 2005;17(4):493–504.PubMedCrossRefGoogle Scholar
  43. 43.
    Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(Suppl 1):S2–10.PubMedGoogle Scholar
  44. 44.
    Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14(3):309–18.PubMedCrossRefGoogle Scholar
  45. 45.
    Abel E, Painter L. Factors that influence adherence to HIV medications: perceptions of women and health care providers. J Assoc Nurses AIDS Care. 2003;14(4):61–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564–73.PubMedGoogle Scholar
  47. 47.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.PubMedCrossRefGoogle Scholar
  48. 48.
    Chang LW, Kagaayi J, Nakigozi G, et al. Telecommunications and health Care: an HIV/AIDS warmline for communication and consultation in Rakai, Uganda. J Int Assoc Physicians AIDS Care (Chic Ill). 2008;7(3):130–2.CrossRefGoogle Scholar
  49. 49.
    Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Dikokole Maqutu
    • 1
    • 2
  • Temesgen Zewotir
    • 1
  • Delia North
    • 1
  • Kogieleum Naidoo
    • 2
  • Anneke Grobler
    • 2
  1. 1.School of Statistics and Actuarial Science, UKZNScottsvilleSouth Africa
  2. 2.CAPRISA, UKZNDurbanSouth Africa

Personalised recommendations